Abstract
Introductiondespite its relatively low case-fatality rate, COVID-19 is a concern with high mortality and morbidity of hospitalized cases. This study was conducted to assess the relationship between time to consultation, presence of respiratory complications at hospital admission and fatal outcome of COVID-19 cases.Methodsthis was a case control study with data collected from records of all patients admitted in the Bafoussam Regional Hospital (BRH) from March 2020 to April 2021. Cases were patients with a fatal outcome and controls were patients that were discharged. The association between the delay in seeking care, dyspnea and blood oxygen level at admission, and fatal outcome was assessed by estimating crude and adjusted odd ratio.Resultsof 400 included patients, 239 (59.75%) were male, 84 (23.73%) health professionals and 144 (36.0%) aged 64 years and above. On admission, 236 patients presented at least one sign of respiratory complication. The mean duration of hospitalization was 11.4 days and 120 (30.0%) admitted patients died. Seeking care before the end of the first day of symptom onset (adjusted (A) OR=0.44 [0.21-0.97]) or within the first three days (AOR=0.48 [0.26-0.89]) significantly reduced the risk of fatal outcome, whereas waiting seven days (AOR=0.74 [0.42-1.33]) did not change this risk. Presenting dyspnea (AOR=2.39 [1.32-4.31]) or blood oxygen level <95% (AOR=3.67 [1.37-9.83]) significantly increased the risk of fatal outcome.Conclusionmortality was one in three patients. Early arrival at the hospital helped to reduce the risk of mortality unlike presenting respiratory complication that increased the risk. Health interventions contributing for early detection and link of COVID-19 cases to care before respiratory complications occur are expected to reduce mortality in COVID-19 patients.
Highlights
Antiviral treatment gap in culturally and linguistically diverse (CALD) populations may be a barrier progress in elimination
We developed a dynamic, deterministic model using three antiviral treatment scale-up scenarios line treatment, intermediate treatment scale-up (80% of 2030), and optimistic scale-up (20% of all HBV by 2022)
The incidence of HBV infection, liver cirrhosis, hepatocellular carcinoma, and HBV-related mortality in four groups of people according to their country of birth
Summary
Abstract #: 1203 Predictors of treatment and survival in hepatocellular carcinoma patients: A Bayesian parametric survival Background: Antiviral treatment gap in culturally and linguistically diverse (CALD) populations may be a barrier progress in elimination. We estimated and predicted of antiviral treatment and migration on HBV burden, related mortality in CALD populations in Australia.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
